Theaterstrasse 8, 
8001 Zurich 

  Tel: +41 44 295 30 45
  Fax +41 44 295 30 46

Congress Presentations

Fingolimod treatment induces changes in NK and T helper cell subpopulations and in T cell co-stimulation markers.
ECTRIMS, October 2015
Barcelona/Spain

Stem cells for Amyotrophic Lateral Sclerosis.
European Academy of Neurology Meeting, June 2015
Berlin/Germany

Adherence and compliance in MS therapy.
Polish Neurological Society, March 2015
Lodz/Poland

Alemtuzumab: restoring the immune system.
Swiss Neurological Society, October 2014
Interlaken/Switzerland

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT).
German Neurological Society, September 2014
Munich/Germany

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis.
ECTRIMS/ACTRIMS Congress, September 2014
Boston/USA

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT).
European Neurological Society Congress, June 2014
Istanbul/Turkey

Prolonged-release fampridine in multiple sclerosis: improved ambulatory function by subject-specific changes of the walking pattern.
American Academy of Neurology Congress, Mai 2014
Philadelphia/USA

Swiss post marketing surveillance monitoring quality of life and treatment.
Journées de Neurologie de Langue Française, April 2014
Strasbourg/France

Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT)
ECTRIMS Congress, October 2013
Copenhagen/Denmark

Therapie der Multiplen Sklerose: vom Cortison zur differenzierten Immunomodulation.
13th Swiss-Russian general Practicioners Conference, Mai 2013
St. Petersburg/Russia

Tysabri in der Behandlung der Multiplen Sklerose
MS State of The Art 2013, March 2013
Lodz/Poland

Novel electrochemiluminescence based immunoassay: neurofilament light chain in serum as a marker of axonal damage
William Harvey Day, Queen Mary University, October 2012
London/United Kingdom

A Swiss best practice experience in three different clinical settings of the 6 hour fingolimod observation procedure.
ECTRIMS Congress, October 2012
Lyon/France

Utilization of JC-Virus antibody testing in clinical practice.
ECTRIMS Congress, October 2012
Lyon/France

Tysabri: new data to efficacy and safety.
Central European Tysabri Advisory Board (CETAB) Meeting, October 2012
Vienna/Austria

Fingolimod in daily practice.
Swiss Neurological Society (SNG) Meeting, Mai 2012
Lugano/Switzerland

Update on current treatment strategies in MS
American Academy of Neurology (AAN) Meeting, participant, April 2012
New Orleans/USA

Tysabri: efficacy and safety update.
Central European Tysabri Advisory Board (CETAB) Meeting, January 2012
Bratislava/Slovakia

Personalized treatment strategies in Multiple Sclerosis.
ECTRIMS Congress, October 2011
Amsterdam/Netherlands

Treatment failure: what to do?
MS State of the Art, January 2011
Lucerne/Switzerland

MS therapy update.
ECTRIMS Congress, October 2010
Göteborg/Sweden

Current therapeutic strategies in MS.
European Neurological Society Congress (participant), June 2010
Berlin/Germany

Oral laquinimod for Multiple Sclerosis.
TEVA Symposium, Mai 2010
Jerusalem/Israel

The effect of IFNbeta 1b treatment on cognition in Multiple Sclerosis.
Advisory Board meeting, March 2010
Rome/Italy

Treatment failure, what to do?
Multiple Sclerosis State of the Art, Januar 2010
Luzern/Switzerland

Safety overview of fingolimod.
Fingolimod Advisory Board, December 2009
Berlin/Germany

New oral agents in the therapy of Multiple Sclerosis.
Cladribine Advisory Board, November 2009
Amsterdam/Netherlands

Phasenadaptierte Therapie der Multiplen Sklerose.
182. Tagung der Schweizerischen Neurologischen Gesellschaft, Juni 2009
Interlaken/Switzerland

Application of the Database Controls in Experimental Trials.
Annual Meeting of St.Lukes Hospital, April 2009
Tokyo/Japan

ALS: Can We Predict the Course of Disease?
19. Kongress des Wissenschaftlichen Beirates der DGM, March 2009
Darmstadt/Germany

Natalizumab in daily practice- risks and benefits.
11th State of the Art Symposium, January 2009
Berne/Switzerland

Strategien zur Optimierung der immunomudulatorischen Therapie der MS.
Zürcher MS-Roundtable, Oktober 2008
Zurich/Switzerland

Moderne Therapie der Multiplen Sklerose
Quadrimed Kongress, Mai 2008
Crans Montana/Switzerland

Reconsidering clinical outcomes: relapses, impairment, disability and beyond.
Symposium of the European Charcot Foundation, November 2007
Fiuggi/Italy

Length of prediagnostic period as a predictor of rate of disease progression and survival in ALS.
17th Meeting of the European Neurological Societ, June 2007
Rhodes/Greece

Slower disease progression and prolonged survival in contemporary ALS patients: is the natural history of ALS changing?
177. Tagung der Schweizerischen Neurologischen Gesellschaft, Oktober 2006
Interlaken/Switzerland

Amyotrophic Lateral Sclerosis: Can We Predict the Course of Disease?
Kongress der Polnischen Neurologischen Gesellschaft, September 2006
Krakow/Poland

Predictability of disease progression in amyotrophic lateral sclerosis.
XVIth Meeting of the European Neurological Society, Mai 2006
Lausanne/Switzerland

Slower disease progression and prolonged survival in contemporary ALS patients: is the natural history of ALS changing?
58th Annual Meeting of American Academy of Neurology, April 2006
San Diego/USA

Predictability of disease progression in amyotrophic lateral sclerosis.
16th International Symposium on ALS/MND, December 2005
Dublin/Ireland

Amyotrophic lateral sclerosis: early predictors of prolonged survival.
World Congress of Neurology, November 2005
Sydney/Australia

Application of the Database Controls in Experimental Trials for Amyotrophic Lateral Sclerosis.
57th Annual Meeting of American Academy of Neurology, April 2005
Miami/USA

Flail arm syndrome: a clinical variant of amyotrophic lateral sclerosis.
XIIIth Meeting of the European Neurological Society, June 2003
Istanbul/Turkey

Pathological crying as the initial presenting symptom in amyotrophic lateral sclerosis.
XIIIth Meeting of the European Neurological Society, June 2003
Istanbul/Turkey

Symptomatic care in ALS
Basler ALS Symposium, March 2003
Basel/Switzerland

Predictive value of T2-lesion volume for the natural course of multiple sclerosis.
Meeting of the Polish Neurological Society, September 200
Poznan/Poland

Rapid progressive, sensory-motor demyelinating neuropathy.
Xth International Neuromuscular Congress, July 2002
Vancouver/Canada

Ice pack test for myasthenia gravis: a simple, noninvasive and safe diagnostic method.
Xth International Neuromuscular Congress, July 2002
Vancouver/Canada

The natural course of multiple sclerosis: predictive value of lesion volume in T2-weighted brain MRI.
XIIth Meeting of the European Neurological Society, June 2002
Berlin/Germany

Necrotising  vasculitis and isotretinoin.
XIIth Meeting of the European Neurological Society, June 2002
Berlin/Germany

 

NeurozentrumBellevue
Theaterstrasse 8, 8001 Zurich

Tel: +41 44 295 30 45
Fax +41 44 295 30 46

Design and implementation: extranet